Liver Transplant Waiting List: Mexico vs USA — What Patients Need to Know

Liver Transplant Waiting List: Mexico vs USA — What Patients Need to Know

If you or someone you love has been diagnosed with end-stage liver disease and is facing the prospect of a transplant, one of the first questions you'll ask is: *How long is the wait?* The answer depends entirely on where you are — and understanding the difference between the liver transplant waiting lists in Mexico and the United States could, quite literally, be a matter of life and death.

In the United States, the average wait time after being added to the national liver transplant list is approximately 240 days, though this varies enormously by blood type, MELD score, and geographic region. In Mexico, the national list paints a more complex picture: the average time from registration to a final outcome is close to 943 days — nearly three years — and patients who have waited more than one year are 12.5 times less likely to receive a transplant than those who receive one in their first year. These numbers underline why timing, surgical access, and living-donor options matter so profoundly.

As a transplant and hepatobiliary surgeon with over 20 years of experience and more than 2,000 procedures performed at Centro Médico González in Mexicali, Baja California — just five minutes from the Calexico, California border crossing — I work with patients from both sides of the border navigating these exact decisions. This guide lays out the facts clearly so you can make an informed choice for yourself or your family.

How the US Liver Transplant Waiting List Works

The UNOS/OPTN System

In the United States, all liver transplant candidates are registered with the Organ Procurement and Transplantation Network (OPTN), administered by the United Network for Organ Sharing (UNOS). The system is a centralized, rules-based allocation framework designed to match available deceased-donor livers to candidates based on medical urgency, compatibility, and geography.

As of 2025, the US performed a record-breaking number of transplants — over 49,000 across all organ types — representing the fifth consecutive year of record highs. Liver transplants specifically increased by 8% compared to 2024, and living-donor liver transplants rose by 17%.

MELD Score: The Key to Your Priority

Your position on the US waiting list is determined primarily by your MELD score (Model for End-Stage Liver Disease), a numeric scale from 6 to 40 that quantifies how urgently you need a liver. The score is calculated using three blood test values:

• Serum creatinine — a measure of kidney function (kidneys are often affected by liver failure)
• Serum bilirubin — a measure of how well the liver processes waste
• INR (International Normalized Ratio) — a measure of blood clotting ability

Most patients are not added to the national waiting list until their MELD score reaches 15 or above, because below that threshold, the risk of surgery outweighs the likelihood of benefit. Patients with MELD scores between 30 and 40 are prioritized first.

How Long Do US Patients Actually Wait?

Wait times in the US vary by blood type, MELD score, and — critically — which region of the country you live in. Nationally, the data shows:

• 39.9% of patients listed received a deceased-donor liver within 3 months (2021 data)
• 45.7% received a transplant within 6 months
• 54.5% received a transplant within 1 year
• The national average is approximately 240 days (8 months) post-listing

However, for patients with blood type O or B, wait times are substantially longer due to compatibility requirements. Patients in high-demand regions such as California and New York also tend to wait longer than those in less populated states.

When the Wait Becomes Dangerous

The most sobering reality of the US system is that not everyone survives the wait. Patients with high MELD scores (30+) face a significant risk of dying or becoming too sick for surgery before a suitable organ becomes available. Every year, thousands of Americans are removed from the transplant list — not because they recovered, but because they deteriorated past the point where surgery could help.

How Mexico's Liver Transplant Waiting List Works

CENATRA and the National Registry

In Mexico, liver transplant candidates are registered through CENATRA (Centro Nacional de Trasplantes), the national transplant coordination body. Unlike the OPTN in the US, Mexico's waiting list functions more as a patient registry than a dynamic, real-time priority queue. Allocation lacks the degree of centralization and transparent urgency-based criteria that the US system provides.

Research published in leading hepatology journals shows that Mexico's waiting list has remained between 300 and 350 active patients at any given year-end for over a decade — a number that appears manageable until you consider the country's population of 130 million people and the relatively low number of deceased-donor transplants performed annually.

The 943-Day Reality

The most important statistic for Mexican patients to understand is this: the average time from registration to final outcome on Mexico's liver transplant waiting list is approximately 943 days — close to 2.6 years. Final outcome includes transplant, death, or administrative removal.

More critically, research tracking patients registered in 2017 found that:

• 21.8% of patients had been waiting five years or more at time of study
• Patients waiting less than 1 year had a probability of receiving a transplant that was 12.5 times higher than those who had waited more than one year
• This creates a perverse dynamic: the longer a patient waits in Mexico's system, the less likely they are to ever receive an organ

Why the Gap Exists

Several structural factors explain the disparity:

• Low organ donation rates: Mexico's deceased-donor rate remains well below regional averages in Latin America and far below the US
• Limited transplant centers: Only a handful of certified transplant centers exist nationally, concentrated in Mexico City and a few major cities
• Regulatory barriers: Coordinating deceased-donor procurement across state lines involves bureaucratic challenges not present in the US OPTN system
• Funding constraints: Public health sector transplant programs face resource limitations that affect the number of procedures performed annually

Living Donor Liver Transplant: The Path That Bypasses the Wait

For both Mexican and American patients, the most reliable way to avoid the wait — in either country's system — is a living-donor liver transplant (LDLT). This option has grown significantly in recent years, and it's one I perform regularly at Centro Médico González.

How Living Donor Liver Transplant Works

The liver is unique among solid organs in its capacity to regenerate. In a living-donor procedure:

1. A compatible donor (typically a first- or second-degree relative, though evaluation includes friends and altruistic donors) undergoes a comprehensive medical and psychological evaluation
2. The donor undergoes resection of either the right hepatic lobe (approximately 60% of the liver) for adult recipients or the left lateral segment for pediatric recipients
3. Both the donor's remaining liver and the recipient's transplanted segment regenerate to near-full volume within 6 to 8 weeks
4. Both patients require separate ICU and recovery periods of 5 to 10 days in hospital

The key advantage: no waiting list. Once a donor is evaluated, cleared, and both parties are medically prepared, the surgery can be scheduled within weeks — not months or years.

Who Can Be a Living Liver Donor?

Donor evaluation at our center follows international protocols and includes:

• Age requirement: 18 to 55 years old (exceptions may apply on a case-by-case basis)
• ABO blood type compatibility with the recipient
• BMI within healthy range (generally below 30)
• No active liver disease, diabetes, or significant cardiovascular history
• Normal liver function tests and imaging (CT volumetry to assess liver size and anatomy)
• Independent psychological evaluation to confirm voluntary, informed decision-making

Dr. César Eduardo González Muñoz personally reviews every donor case to ensure both patient safety and ethical compliance with Mexican COFEPRIS regulations and international transplant guidelines.

Living Donor Outcomes

In experienced centers, outcomes for living-donor liver transplant are excellent and comparable to deceased-donor procedures:

• 1-year patient survival: 85–92%
• 5-year patient survival: 72–82%
• Donor mortality risk: less than 0.1–0.5% at experienced centers
• Donor complication rate: 20–40% minor complications (bile leak, wound infection), most managed without reoperation

These statistics reflect international benchmarks; outcomes at individual centers vary and should be discussed directly with your surgeon.

Mexicali as a Cross-Border Option for US Patients

The Geographic Advantage

For patients in California, Arizona, Nevada, and neighboring states, Mexicali offers a logistically compelling option. Centro Médico González is located at Blvd. Francisco L. Montejano 1188, Fracc. Fovissste, 21020 Mexicali, B.C. — approximately five minutes from the Calexico, California border crossing. Patients can:

• Drive from San Diego in under 3 hours
• Cross from Los Angeles in approximately 4.5 hours
• Fly into Mexicali International Airport directly from major US cities

This proximity means pre-operative consultations, lab work, and imaging can be completed with minimal travel disruption, and family members can easily be present during recovery.

Medical Standards and Accreditation

Our facility operates under the full oversight of COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) — Mexico's federal health regulatory body. Dr. González holds Cédula 8274619 and COFEPRIS registration 21020353A00412, is board-certified by the Consejo Mexicano de Cirugía General, and has trained at internationally recognized centers throughout his career.

Transplant care at our center includes:

• Advanced hepatobiliary imaging (CT, MRI, Doppler ultrasound)
• Full ICU capacity with hepatology nursing staff
• Immunosuppression management protocols aligned with international guidelines (tacrolimus, mycophenolate mofetil, corticosteroids)
• Long-term follow-up coordination, including telemedicine support for US-based patients

What US Patients Need to Know Before Coming

Before traveling for a liver transplant evaluation at Centro Médico González, US patients should:

1. Gather their medical records: Complete hepatology workup including MELD score history, recent LFTs (ALT, AST, GGT, alkaline phosphatase, bilirubin, albumin), INR, CBC, and BMP
2. Identify a potential living donor: If a family member or friend is willing to be evaluated, their basic labs can be included in the initial virtual consultation
3. Understand post-transplant follow-up: Immunosuppression management requires regular monitoring; we provide telemedicine coordination with your US-based internist or gastroenterologist
4. Review travel and insurance implications: Most US health insurance plans do not cover international transplant procedures; patients should plan accordingly

Key Differences at a Glance

US vs Mexico Liver Transplant System Comparison

The United States system offers a centralized, transparent, urgency-based allocation framework under OPTN/UNOS, with an average deceased-donor wait of approximately 240 days and a strong infrastructure of over 140 transplant centers. The principal challenge is supply: demand for livers far exceeds availability, and wait times in high-population regions can be significantly longer than the national average.

Mexico's national system, administered through CENATRA, faces structural challenges that extend average waits to nearly three years and create a counterintuitive dynamic where longer waits correlate with lower transplant probability. However, for patients pursuing a living-donor transplant through a specialized private center — such as Centro Médico González in Mexicali — the wait is eliminated. Procedures can be scheduled based on medical readiness rather than organ availability.

The practical implication for US patients: if you have a compatible willing living donor, pursuing a living-donor liver transplant with a board-certified hepatobiliary surgeon in Mexicali can be faster than waiting for a deceased-donor organ in either country's public system.

Post-Transplant Immunosuppression and Long-Term Management

One aspect of liver transplant care that patients often underestimate is the lifelong nature of post-transplant management. Successfully receiving a liver is the beginning of a new medical chapter, not the end.

Standard Immunosuppression Protocol

Following liver transplantation, recipients require immunosuppressive therapy to prevent acute and chronic rejection. The standard protocol includes:

• Tacrolimus (Prograf/Advagraf): The cornerstone calcineurin inhibitor. Blood levels are monitored frequently (daily during initial hospitalization, then weekly, then monthly) and doses adjusted to maintain therapeutic ranges (typically 8–12 ng/mL in the early period, tapering over time)
• Mycophenolate mofetil (CellCept): An antiproliferative agent used in combination with tacrolimus to reduce rejection risk
• Corticosteroids (prednisone/methylprednisolone): Used in higher doses immediately post-transplant and tapered over 3–6 months in most patients

Monitoring Schedule

Post-transplant follow-up at our center includes:

• Week 1–4: Twice-weekly lab panels (LFTs, tacrolimus levels, creatinine, CBC)
• Month 2–3: Weekly labs as immunosuppression is adjusted
• Month 4–12: Monthly labs with outpatient hepatology review
• Year 2+: Quarterly labs with annual imaging

US-based patients coordinate their local laboratory monitoring with their referring hepatologist or internist, with results reviewed by Dr. González's team via telemedicine.

Rejection, Infection, and Long-Term Risks

Patients and families should understand that immunosuppression carries trade-offs. The three main long-term risks to monitor are:

• Acute cellular rejection: Most commonly occurs in the first 3–6 months. Treated with high-dose corticosteroid pulses and/or adjustment of tacrolimus dosing
• Opportunistic infections: Suppressed immunity increases susceptibility to CMV, Pneumocystis jirovecii pneumonia (PJP), and fungal infections. Prophylaxis protocols are standard
• Chronic allograft dysfunction and recurrent disease: In patients transplanted for viral hepatitis or metabolic liver disease, recurrence monitoring is essential

Frequently Asked Questions

How long is the liver transplant waiting list in Mexico compared to the USA? In the United States, the average wait after listing is approximately 240 days (8 months) for a deceased-donor liver, though this varies significantly by region and blood type. In Mexico's national CENATRA system, the average time from registration to a final outcome is approximately 943 days — nearly three years. Patients who pursue a living-donor transplant at a private specialized center bypass the public waiting list entirely and can schedule surgery based on medical readiness.

What is a MELD score and how does it affect my place on the liver transplant list? MELD (Model for End-Stage Liver Disease) is a score from 6 to 40 that quantifies how urgently you need a liver transplant. It is calculated from three blood tests: serum creatinine, bilirubin, and INR. In the US system, patients with the highest MELD scores (30–40) are prioritized first. Patients are typically not listed until their MELD reaches 15. Your MELD score is recalculated regularly to reflect your current health status.

Can a US citizen get a liver transplant in Mexico? Yes. International patients regularly receive liver transplants at specialized private centers in Mexico, particularly through living-donor procedures. There is no legal or medical barrier to cross-border transplantation. The critical factors are choosing a board-certified, credentialed surgeon operating in an accredited facility, and ensuring proper pre- and post-operative coordination with your US-based medical team.

Who can donate part of their liver as a living donor? A living liver donor must generally be between 18 and 55 years old, have a compatible blood type, maintain a healthy BMI (generally below 30), have no active liver disease or significant cardiovascular history, and pass a comprehensive medical and psychological evaluation. The evaluation process at Centro Médico González is thorough and prioritizes donor safety above all other considerations.

What happens after a liver transplant — how long is recovery? Most patients remain in the hospital for 7 to 14 days following liver transplantation, with an ICU stay of 2 to 5 days immediately post-surgery. Full recovery — meaning return to daily activities — typically occurs within 6 to 12 weeks. However, medical follow-up, lab monitoring, and immunosuppression management are lifelong commitments. Patients taking tacrolimus will have regular blood level checks for the rest of their lives.

What are the survival rates for liver transplantation? At experienced transplant centers, 1-year patient survival rates are approximately 85–90% and 5-year survival rates are approximately 72–80%. These figures are comparable between living-donor and deceased-donor procedures when performed by experienced surgical teams. Outcomes depend on the underlying diagnosis, MELD score at time of transplant, recipient age and comorbidities, and post-transplant adherence to immunosuppression.

Does US health insurance cover a liver transplant in Mexico? Most US private health insurance plans and Medicare do not cover organ transplant procedures performed outside the United States. Patients pursuing transplantation in Mexico at a private center should plan for out-of-pocket expenses. We encourage patients to review their specific plan benefits and consult with our patient coordination team, who can provide detailed estimates and financing guidance.

What conditions most commonly lead to needing a liver transplant? The most frequent diagnoses leading to liver transplantation are end-stage liver disease from alcohol-associated liver disease (ALD), non-alcoholic steatohepatitis (NASH/MASLD), chronic hepatitis B and C, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and hepatocellular carcinoma (HCC) meeting Milan or UCSF criteria.

Related Articles

Continue your research on liver transplantation and hepatobiliary care:

• Liver Transplant in Mexicali: Expert Hepatobiliary Surgeon Near the US Border
• Living Donor Liver Transplant: The Fastest Path to a New Liver
• End-Stage Liver Disease: Treatment Options in Mexico
• Portal Hypertension Surgery: When It's Needed and Why Timing Matters
• Liver Cirrhosis Treatment in Mexico: A Comprehensive Guide

Take the First Step

If you or a loved one has been diagnosed with end-stage liver disease and you are exploring your options — whether you're currently on a US waiting list, considering evaluation in Mexico, or investigating the living-donor path — I invite you to schedule a consultation at Centro Médico González.

Dr. César Eduardo González Muñoz and his team offer comprehensive evaluation, from initial imaging review to living-donor workup to full transplant coordination. Our clinic is located at Blvd. Francisco L. Montejano 1188, Fracc. Fovissste, 21020 Mexicali, B.C., and we are reachable by phone at +52-686-338-3848. For US patients, we offer telemedicine consultations prior to your first in-person visit.

The wait can be life-threatening. If you have the option of pursuing a living-donor transplant, the time to explore it is now.